慢性心力衰竭应用卡维地洛联合缬沙坦治疗的可行性研究被引量：3

The Feasibility Study of Carvedilol Combined with Valsartan in the Treatment of Chronic Heart Failure

下载PDF

导出

摘要目的研究卡维地洛联合缬沙坦治疗慢性心力衰竭的可行性。方法选取我院慢性心力衰竭患者50例,随机分为两组,均采取常规治疗,联合组于常规治疗同时采取卡维地洛联合缬沙坦治疗,比较两组疗效。结果联合组治疗总有效率92.00%高于对照组76.00%(P<0.05)。结论卡维地洛联合缬沙坦治疗慢性心力衰竭临床疗效显著。 Objective To study the feasibility of carvedilol combined with valsartan in the treatment of chronic heart failure. Methods A total of 50 cases of chronic heart failure patients in our hospital were randomly divided to two groups, they were treated with conventional therapy and combination group. The combined group was treated with carvedilol combined with valsartan, Clinical efficacy of two groups was compared. Results The total effective rate of the combined group was 92.00% higher than that of the control group 76.00% （P〈0.05）. Conclusion Clinical efficacy of carvedilol and valsartan significantly in the treatment of chronic heart failure is good.

作者徐东

机构地区哈尔滨市第一医院老干部病房

出处《中国继续医学教育》 2016年第18期141-142,共2页 China Continuing Medical Education

关键词慢性心力衰竭卡维地洛缬沙坦 Chronic heart failure Carvedilol Valsartan

分类号 R541.6 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献7

1李雅,李朱勤.卡维地洛联合缬沙坦治疗36例慢性心力衰竭[J].上海医药,2016,37(5):21-22. 被引量：7
2战云.卡维地洛联合缬沙坦治疗慢性心力衰竭临床效果及安全性探究[J].中国卫生标准管理,2015,6(6):252-253. 被引量：6
3崔艳菁.卡维地洛联合缬沙坦治疗慢性心力衰竭临床效果及安全性分析[J].中国继续医学教育,2015,7(28):117-118. 被引量：9
4许秋仁.缬沙坦联合卡维地洛治疗慢性心力衰竭的临床效果观察[J].现代诊断与治疗,2015,26(10):2267-2268. 被引量：12
5李朋,李睿,徐建辉,杨海珍.卡维地洛治疗慢性心力衰竭的随机对照研究[J].中国卫生标准管理,2015,6(23):126-127. 被引量：3
6邱正新.卡维地洛联合缬沙坦治疗慢性心功能衰竭临床观察[J].中国现代药物应用,2014,8(10):139-140. 被引量：10
7孔戴艳.慢性心力衰竭应用卡维地洛联合缬沙坦治疗的效果及安全性[J].药物与人,2014,27(5):70-70. 被引量：1

二级参考文献33

1夏华玲,李迎春,黄中云.缬沙坦治疗慢性心力衰竭疗效观察[J].临床医学,2006,26(3):36-37. 被引量：13
2Kourea K, Parissis JT, Farmakis D,et al. Effects of darbepoet in- alphaon plasma pro-inflammatory cytokines,anti-inflammatom eytokine interl-eukin-10 and soluble Fas/Fas ligand system in anemic:patients with chro-nic heart failure.Atherosclerosis, 2008, 199(1):215-221.
3刘光安.缬沙坦联合卡维地洛治疗慢性心力衰竭的临床疗效[J].医药前沿,2014,4(11):9-10.
4曾盛芝.卡维地洛联合缬沙坦治疗慢性心力衰竭临床效果及安全性探究[J].中国保健营养(上旬刊),2014,24(3):1579.
5Schroten NF, Damman K, Hemmelder MH, et al. Effect of additive renin inhibition with aliskiren on renal blood flow in patients with chronic heart failure and renal dysfunction (additive renin inhibition with aliskiren on renal blood flow and neurohormonal activation in patients with chronic heart failure and renal dysfunction)[J]. Am Heart J, 2015, 169(5): 693-701.e3.
6Mudd JO, Kass DA. Tackling heart failure in the twenty-first century[J]. Nature, 2008, 451(7181): 919-928.
7Schmaltz AA. Chronic congestive heart failure in infancy and childhood: new aspects of diagnosis and treatment[J]. Klin Padiatr, 2015, 227(1): 3-9.
8Berezin AE, Kremzer AA, Berezina TA, et al. Pattern of circulating microparticles in chronic heart failure patients with metabolic syndrome: relevance to neurohumoral and inflammatory activation[J]. BBA Clin, 2015, 4: 69-75.
9Lillyblad MP. Dual angiotensin receptor and neprilysin inhibition with sacubitril/valsartan in chronic systolic heart failure: understanding the new PARADIGM[J]. Ann Pharmacother. 2015, 49(11): 1237-1251.
10Fr6hlich H, Zhao J, T/iger T, et al. Carvedilol compared with metoprolol succinate in the treatment and prognosis of patients with stable chronic heart failure: carvedilol or metoprolol evaluation study[J]. Circ Heart Fail, 2015, 8(5): 887-896.